Compelo Medical Devices - Latest industry news and analysis is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More

SRI wins NIAID grant for topical microbicide gel development

SRI International has received a new grant from the National Institute of Allergy and Infectious Diseases (NIAID) to develop a topical microbicide gel for drug delivery.

The topical microbicide gel, which will be based on a patented bioadhesive polymeric platform, is a combination therapy against human immunodeficiency virus (HIV) and herpes simplex virus type 2 (HSV-2) infections in women.

As part of the grant, SRI’s researchers will test a prototype bioadhesive formulation for sustained delivery of the antiviral drugs tenofovir and acyclovir to the vaginal surface.

The company said the awarded grant is for two years with a possible extension of three additional years.

SRI Biosciences Formulations R&D director Gita Shankar said the easy-to-use combination therapy in development could help contain the spread of HIV and HSV, and possibly other sexually transmitted diseases.

"One of the strongest benefits of a topical gel formula is that it can offer protection when options such as condoms are unavailable or unacceptable," Shankar added.